首页> 外文期刊>Neurobiology of Stress >Pioglitazone, a PPARγ agonist rescues depression associated with obesity using chronic unpredictable mild stress model in experimental mice
【24h】

Pioglitazone, a PPARγ agonist rescues depression associated with obesity using chronic unpredictable mild stress model in experimental mice

机译:吡格列酮,一种PPARγ激动剂,使用慢性不可预测的轻度应激模型在实验小鼠中挽救了与肥胖相关的抑郁症

获取原文
       

摘要

Pioglitazone, a peroxisome proliferator activated receptor gamma (PPARγ) agonist belonging to thiazolidinedione class, is mainly used in diabetes mellitus. Obese subjects are twice likely to become depressed than non-obese individuals. The biological mechanisms linking depression with obesity still remain poorly understood and there is immense need for better therapeutic intervention against such co-morbid disorders. The present study investigates the effect of pioglitazone on the chronic unpredictable mild stress (CUMS) induced depression in obese mice by using behavioral tests and biochemical estimations. Mice were fed with high fat diet (HFD) for 14 weeks and were further subjected to different stress procedures for 28 days to induce depressive behavior. Animals were administered orally with pioglitazone (30?mg/kg p.o.)/escitalopram (10?mg/kg p.o.)/vehicle (10?ml/kg p.o.) daily from day 15–28. Various behavioral paradigms such as sucrose preference test, forced swim test (FST), tail suspension test (TST) and elevated plus maze (EPM) were performed. Biochemical estimations including plasma glucose, total cholesterol, triglycerides, and total proteins were performed. The data obtained from behavioral assays and biochemical assessments indicated that obese animals exhibited severe depressive-like behavior compared to non-obese animals. Furthermore, obese animals subjected to CUMS worsen the depressive behavior compared to obese control animals. Repetitive treatment with pioglitazone reversed the CUMS induced behavioral and biochemical alterations in HFD fed obese mice which atleast in part may be mediated through improving altered plasma glucose. The study suggests that pioglitazone needs further attention with respect to molecular mechanisms that could provide a better therapeutic strategy against depression associated with obesity. Graphical abstract Display Omitted Highlights ? Obese animals subjected to chronic stress worsens depressive symptoms. ? Altered plasma glucose involved in depression co-morbid with obesity. ? Pioglitazone inhibited behavioral alterations in obese mice subjected to stress. ? Pioglitazone attenuated the biochemical changes in obese mice subjected to stress. ? Antidepressant-like effect of pioglitazone in depression associated with obesity.
机译:吡格列酮是一种过氧化物酶体增殖物激活的受体γ(PPARγ)激动剂,属于噻唑烷二酮类,主要用于糖尿病。肥胖的人比非肥胖的人容易抑郁的可能性是两倍。关于抑郁与肥胖的生物学机制仍然知之甚少,并且迫切需要针对这种合并症的更好的治疗干预措施。本研究通过行为测试和生化评估研究了吡格列酮对肥胖小鼠慢性不可预测的轻度应激(CUMS)诱导的抑郁的影响。给小鼠饲喂高脂饮食(HFD)14周,并使其经受不同的应激程序28天,以诱发抑郁行为。从第15-28天开始,每天给动物口服吡格列酮(30?mg / kg p.o。)/依他普仑(10?mg / kg p.o。)/载体(10?ml / kg p.o.)。进行了各种行为范例,例如蔗糖偏爱测试,强迫游泳测试(FST),尾巴悬吊测试(TST)和高架迷宫(EPM)。进行了包括血浆葡萄糖,总胆固醇,甘油三酸酯和总蛋白质在内的生化评估。从行为分析和生化评估获得的数据表明,与非肥胖动物相比,肥胖动物表现出严重的抑郁样行为。此外,与肥胖对照动物相比,经受CUMS的肥胖动物使抑郁行为恶化。吡格列酮的重复治疗逆转了CUMS诱导的HFD喂养的肥胖小鼠的行为和生化改变,其中至少部分可能是通过改善改变的血糖来介导的。研究表明吡格列酮在分子机制方面需要进一步关注,以提供更好的治疗方法来治疗肥胖相关的抑郁症。图形摘要显示省略的突出显示?患有慢性应激的肥胖动物会使抑郁症状恶化。 ?参与抑郁症的血浆葡萄糖变化与肥胖症并存。 ?吡格列酮抑制了承受压力的肥胖小鼠的行为改变。 ?吡格列酮减弱了承受压力的肥胖小鼠的生化变化。 ?吡格列酮在与肥胖相关的抑郁症中具有抗抑郁样作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号